

## **AMENDMENTS TO THE SPECIFICATION**

***Please amend paragraph [0014], beginning on page 4, line 17 as follows:***

[0014]

Fig. 1 shows changes in partial pressure of arterial carbon dioxide (PaCO<sub>2</sub>) of 12 patients for the period from before the 1<sup>st</sup> administration period until the end of the 6<sup>th</sup> administration period, during which 2 ampules of "Radicut injection 30 mg" were administered daily in Example 2.

Fig. 2 shows the evaluation schedule of ALSFRS-R (Revised ALS functional rating scale) for patients of Example 1.

***Please delete paragraph [0054], beginning on page 20, line 18, and ending on page 21, line 1, in its entirety, including the illustration.***

***Please amend paragraph [0056], beginning on page 22, line 23 as follows:***

[0056]

b) Assessment based on cumulative differences

~~Table 2~~Table 1 shows results of assessment based on cumulative differences of individual cases of each drug administration group in accordance with ALSFRS-R. The suppression rates (rates of "suppressed") were 20% (1 out of 5 cases) in the 30 mg group, and 50% (7 out of 14 cases) in the 60 mg group.

***Please amend paragraph [0057], beginning on page 22, line 29 as follows:***

[0057]

~~[Table 2]~~[Table 1]

Assessment based on cumulative differences in accordance with ALSFRS-R				
Drug administration group	Assessment			
	Suppressed	Slightly suppressed	No change	Suppression rate
30 mg group	1	3	1	20.0%
60 mg group	7	1	6	50.0%

***Please amend paragraph [0067], beginning on page 25, line 10 as follows:***

[0067]

~~[Table 3]~~[Table 2]

Examined component	Before administration	After administration
GOT (IU/L)	21.3	19.1
GPT (IU/L)	22.2	19.6
$\gamma$ -GTP (IU/L)	31.6	25.3
BUN (mg/dl)	14.1	14.3
Creatinine (mg/dl)	0.6	0.6
CK (IU/L)	165.3	135.6